Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large growth in short interest in May. As of May 29th, there was short interest totaling 1,068,991 shares, a growth of 173.2% from the May 14th total of 391,277 shares. Currently, 44.8% of the company’s shares are sold short. Based on an average daily trading volume, of 110,754,674 shares, the short-interest ratio is presently 0.0 days.

Virax Biolabs Group Stock Performance

Shares of Virax Biolabs Group stock traded down $0.01 during trading on Friday, reaching $0.18. 613,547 shares of the stock were exchanged, compared to its average volume of 17,264,074. The stock’s fifty day moving average is $0.18 and its 200 day moving average is $0.26. Virax Biolabs Group has a 1 year low of $0.10 and a 1 year high of $1.14.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Virax Biolabs Group presently has a consensus rating of “Hold” and an average target price of $1.00.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.